Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 5.23
CYTK's Cash-to-Debt is ranked lower than
62% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. CYTK: 5.23 )
Ranked among companies with meaningful Cash-to-Debt only.
CYTK' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.83  Med: 10.11 Max: No Debt
Current: 5.23
Equity-to-Asset 0.56
CYTK's Equity-to-Asset is ranked lower than
63% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CYTK: 0.56 )
Ranked among companies with meaningful Equity-to-Asset only.
CYTK' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.46  Med: 0.65 Max: 0.91
Current: 0.56
-1.46
0.91
Interest Coverage 7.39
CYTK's Interest Coverage is ranked lower than
87% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CYTK: 7.39 )
Ranked among companies with meaningful Interest Coverage only.
CYTK' s Interest Coverage Range Over the Past 10 Years
Min: 6.93  Med: 5031.9 Max: No Debt
Current: 7.39
Piotroski F-Score: 6
Altman Z-Score: 2.01
Beneish M-Score: 4.43
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 17.56
CYTK's Operating Margin % is ranked higher than
85% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. CYTK: 17.56 )
Ranked among companies with meaningful Operating Margin % only.
CYTK' s Operating Margin % Range Over the Past 10 Years
Min: -1926.08  Med: -272.6 Max: 32
Current: 17.56
-1926.08
32
Net Margin % 15.46
CYTK's Net Margin % is ranked higher than
86% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. CYTK: 15.46 )
Ranked among companies with meaningful Net Margin % only.
CYTK' s Net Margin % Range Over the Past 10 Years
Min: -1912.57  Med: -244.9 Max: 30.1
Current: 15.46
-1912.57
30.1
ROE % 23.31
CYTK's ROE % is ranked higher than
94% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. CYTK: 23.31 )
Ranked among companies with meaningful ROE % only.
CYTK' s ROE % Range Over the Past 10 Years
Min: -85.46  Med: -50.79 Max: 32.47
Current: 23.31
-85.46
32.47
ROA % 12.41
CYTK's ROA % is ranked higher than
92% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. CYTK: 12.41 )
Ranked among companies with meaningful ROA % only.
CYTK' s ROA % Range Over the Past 10 Years
Min: -73.2  Med: -36.09 Max: 23.37
Current: 12.41
-73.2
23.37
ROC (Joel Greenblatt) % 185.73
CYTK's ROC (Joel Greenblatt) % is ranked higher than
96% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. CYTK: 185.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CYTK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3507.33  Med: -583.53 Max: 710.88
Current: 185.73
-3507.33
710.88
3-Year Revenue Growth Rate 30.50
CYTK's 3-Year Revenue Growth Rate is ranked higher than
79% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. CYTK: 30.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CYTK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -32.1 Max: 154.5
Current: 30.5
0
154.5
GuruFocus has detected 3 Warning Signs with Cytokinetics Inc $CYTK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CYTK's 10-Y Financials

Financials (Next Earnings Date: 2017-04-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CYTK Guru Trades in Q1 2016

Charles Brandes Sold Out
Paul Tudor Jones 15,008 sh (-45.76%)
Jim Simons 184,479 sh (-64.47%)
» More
Q2 2016

CYTK Guru Trades in Q2 2016

Paul Tudor Jones 16,470 sh (+9.74%)
Jim Simons Sold Out
» More
Q3 2016

CYTK Guru Trades in Q3 2016

Paul Tudor Jones 41,300 sh (+150.76%)
» More
Q4 2016

CYTK Guru Trades in Q4 2016

Paul Tudor Jones 17,240 sh (-58.26%)
» More
» Details

Insider Trades

Latest Guru Trades with CYTK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:VNDA, NAS:RVNC, NAS:AMRI, NAS:CTMX, NAS:ARDX, NAS:ATRA, NAS:ANIK, NAS:ACIU, NAS:ENTA, NAS:WVE, NAS:RGNX, NAS:MGNX, NAS:XBIT, NAS:AUPH, NAS:ACHN, NAS:ANIP, NAS:OMER, NAS:PGNX, NAS:KERX, OTCPK:IPHYF » details
Traded in other countries:KK3A.Germany,
Headquarter Location:USA
Cytokinetics Inc is a biopharmaceutical company engaged in the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.

Cytokinetics is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatment for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility.

Top Ranked Articles about Cytokinetics Inc

Cytokinetics Added to S&P SmallCap 600
Cytokinetics to Announce First Quarter Results on April 27, 2017
Cytokinetics to Present at the 16th Annual Needham Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (NASDAQ:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 10:40 AM ET at the Westin Grand Central Hotel in New York.
Interested parties may access the live webcast of this presentation by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The webcast replay of the presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics' website for 90 days following the conclusion of the event. About Cytokinetics Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal troponin activator (FSTA). Tirasemtiv is the subject of VITALITY-ALS, an international Phase 3 clinical trial in patients with ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency. Cytokinetics is preparing for the potential commercialization of tirasemtiv in North America and Europe and has granted an option to Astellas for development and commercialization in other countries. Cytokinetics is collaborating with Astellas to develop CK-2127107, a next-generation fast skeletal muscle activator. CK-2127107 is the subject of two ongoing Phase 2 clinical trials enrolling patients with spinal muscular atrophy and chronic obstructive pulmonary disease. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator. Omecamtiv mecarbil is the subject of GALACTIC-HF, an international Phase 3 clinical trial in patients with heart failure. Amgen holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and certain other countries. Astellas holds an exclusive worldwide license to develop and commercialize CK-2127107. Licenses held by Amgen and Astellas are subject to Cytokinetics' specified co-development and co-commercialization rights. For additional information about Cytokinetics, visit http://www.cytokinetics.com/. Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act’s safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to planned presentations, and the properties and potential benefits of Cytokinetics’ drug candidates and potential drug candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.
Contact:
Cytokinetics
Diane Weiser
Vice President, Corporate Communications, Investor Relations
(650) 624-3060

Read more...
Origent Data Sciences and Cytokinetics Advance Collaboration Intended to Validate Predictive Analytics Model in ALS

Research Aimed at Accelerating Conduct of Clinical Trials

VIENNA, Va. AND SOUTH SAN FRANCISCO, Calif., March 23, 2017 (GLOBE NEWSWIRE) -- Origent Data Sciences, Inc. (Origent) and Cytokinetics, Inc. (NASDAQ:CYTK) today announced the advancement of their research collaboration to prospectively validate Origent’s computer model to predict the course of ALS (amyotrophic lateral sclerosis) disease progression using data from VITALITY-ALS, Cytokinetics’ ongoing Phase 3 clinical trial of tirasemtiv. Funded by a grant from The ALS Association to Origent, this joint research program is designed to enable the first prospective validation of the predictive model in a clinical trial. Previously, the Origent models predicting both function and survival of ALS patients have been validated using the placebo arms of retrospective clinical trial datasets.
Because ALS disease progression is heterogeneous among patients, predicting an individual patient’s course is difficult. This heterogeneity creates challenges for the design and conduct of clinical trials as inclusion of patients who progress at variable and unpredictable rates requires larger, longer and more expensive trials in order to observe a potential treatment effect of a therapeutic intervention. Origent’s statistical models are designed to identify the patients whose symptoms are likely to progress quickly or slowly, potentially providing a methodology to address the complexity created by disease heterogeneity. Results from the first part of the research collaboration were presented at the 27th International Symposium on ALS/MND and showed that the Gradient Boosting Machine (GBM) algorithm was the optimal model to predict slow vital capacity (SVC) at times subsequent to baseline and that forced vital capacity (FVC) records could be used to predict SVC scores of ALS patients using this machine learning technique. “Following the successful completion of the retrospective validation of our predictive models using baseline characteristics data from BENEFIT-ALS, the Phase 2 b trial of tirasemtiv, we look forward to taking this research collaboration to the next level and thank Cytokinetics for providing us access to the first real-time dataset for the prospective analysis of patients with ALS, ” said Dave Ennist, Chief Science Officer, Origent Data Sciences. “The predictive power of the Origent computer model is encouraging, particularly the ability to predict slow vital capacity subsequent to baseline, as demonstrated in the first phase of the research,” said Jinsy Andrews, M.D., Director of Neuromuscular Clinical Trials at Columbia University and Medical Monitor for VITALITY-ALS. “We are pleased to continue this groundbreaking collaboration which we hope may pave the way towards increased efficiencies in the conduct of clinical trials in patients with ALS.” About the Research Collaboration Origent will seek to prospectively validate existing predictive models (including the ALSFRS-R, respiratory, gross, fine, and bulbar sub-scores, SVC and survival models) using baseline characteristics data from VITALITY-ALS, the ongoing Phase 3 clinical trial to assess the effects of tirasemtiv versus placebo on SVC and other measures of skeletal muscle strength in patients with ALS. Tirasemtiv is a fast skeletal troponin activator (FSTA) being developed by Cytokinetics for the potential treatment of patients with ALS. Using existing models in Origent's library, predictions will be made for each patient using only screening and baseline information from the placebo arm of the trial. Screening and baseline data of placebo patients will be provided following database lock and predictions will be made in the absence of access to the subsequent outcomes of the patients from the placebo arm of VITALITY-ALS. After the predictions are complete, clinical outcomes data from patients in the placebo arm of VITALITY-ALS will be made accessible to Origent for comparing actual placebo outcomes data to the previously escrowed predictions. About Origent Data Sciences Origent Data Sciences, Inc. is a spinoff of Sentrana, Inc., a pioneer in the field of Precision Sales and Marketing and winner of the DREAM Phil Bowen ALS Prediction Prize4Life Challenge. Since 2004, Sentrana has been a market leader in operationalizing new applications using predictive technologies. Similarly, Origent has become the market leader in patient-level predictive modeling for neurological conditions including ALS, and has developed many new applications to manage and reduce drug development risks through better foresight. Rather than considering a similar historic patient to act “the same” as a current patient, Origent treats and models each individual patient separately, predicting their behavior individually. By modeling patient-level dynamics rather than the characteristics of a population, Origent’s tools uncover a deep level of insight that allows biostatisticians and researchers to gain clearer understanding and greater knowledge from their data.  For additional information about Origent, visit www.origent.com. About Cytokinetics Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal troponin activator (FSTA). Tirasemtiv is the subject of VITALITY-ALS, an international Phase 3 clinical trial in patients with ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency. Cytokinetics is preparing for the potential commercialization of tirasemtiv in North America and Europe and has granted an option to Astellas for development and commercialization in other countries. Cytokinetics is collaborating with Astellas to develop CK-2127107, a next-generation fast skeletal muscle activator. CK-2127107 is the subject of two ongoing Phase 2 clinical trials enrolling patients with spinal muscular atrophy and chronic obstructive pulmonary disease. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator. Omecamtiv mecarbil is the subject of GALACTIC-HF, an international Phase 3 clinical trial in patients with heart failure. Amgen holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and certain other countries. Astellas holds an exclusive worldwide license to develop and commercialize CK-2127107. Licenses held by Amgen and Astellas are subject to Cytokinetics' specified co-development and co-commercialization rights. For additional information about Cytokinetics, visit www.cytokinetics.com. Cytokinetics Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities, including Cytokinetics’ and Origent’s predictive analytics research and the ability to validate Origent’s predictive technology; the initiation, conduct, design, enrollment, progress, continuation, completion and results of clinical trials; the significance and utility of preclinical study and clinical trial results, the expected availability of clinical trial results, planned interactions with regulatory authorities and the outcomes of such interactions; and the significance and utility of Origent’s predictive modeling. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the U.S. Food and Drug Administration (FDA) or foreign regulatory agencies may not accept the utility of predictive modeling, including its utility in clinical trial design; the FDA or foreign regulatory agencies may delay or limit Cytokinetics' or its partners' ability to conduct clinical trials; and Cytokinetics may incur unanticipated research and development and other costs or be unable to obtain additional financing necessary to conduct development of its products. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact:
Cytokinetics
Diane Weiser
Vice President, Corporate Communications, Investor Relations
(650) 624-3060

Read more...
Cytokinetics Announces Preclinical Data for CK-2127107 Presented at MDA Scientific Conference

Next-Generation Fast Skeletal Troponin Activator Improves Muscle Function in Mouse Models of Spinal Muscular Atrophy

SOUTH SAN FRANCISCO, Calif., March 22, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (NASDAQ:CYTK) today announced that preclinical data for CK-2127107 were presented at the MDA Scientific Conference in Arlington, VA, showing that this next-generation fast skeletal troponin activator (FSTA) improves muscle function in mouse models of spinal muscular atrophy (SMA). In collaboration with Astellas Pharma Inc. (TSE:4503) ("Astellas"), Cytokinetics is developing CK-2127107 as a potential treatment for people living with SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue.
“These data support our ongoing Phase 2 clinical trial of CK-2127107 in adolescent and adult patients with SMA,” said Fady I. Malik, MD, PhD, Cytokinetics' Executive Vice President, Research and Development. “The increased muscle force at sub-maximal nerve stimulation frequencies in mice inform the potential for CK-2127107 to increase muscle function in patients living with motor neuron dysfunction.” Preclinical Study Design and Results
The objective of this study was to investigate the effect of CK-2127107 on skeletal muscle function in two mouse models of SMA with varying levels of disease severity. The study evaluated CK-2127107 in 2B/2B-Neo Intermediate SMA mice (similar to Type II SMA), in collaboration with Lurie Children’s Hospital and Hung Li SMA mice (similar to Types III and IV SMA).  These mouse models exhibit significant nerve dysfunction and/or muscle atrophy and a decrease in maximum muscle force production. Muscle force production was assessed by electrical stimulation of the sciatic nerve and plantar flexor force was measured in response to a range of stimulation frequencies (10-200Hz). Single doses of CK-2127107 increased isometric force in situ in response to sub-tetanic nerve stimulation in both mouse models. In the 2B/2B-Neo SMA mice, force output at a physiologically relevant sub-tetanic stimulation frequency (30Hz) was significantly increased following dosing of CK-2127107 at 10 mg/kg (p<0.01) and 30 mg/kg (p<0.001).  In the Hung Li SMA mice, force output at sub-tetanic (30Hz) nerve stimulation increased with 30 mg/kg of CK-2127107 to levels higher than wild-type control mice (p<0.001).  In both the 2B/2B Neo and Hung Li SMA mouse models there was a leftward shift of the force-frequency response curve indicating a calcium sensitizing effect of CK-2127107 in the skeletal muscle of these mouse models of SMA with nerve dysfunction and muscle atrophy. These results suggest that CK-2127107 and other FSTAs may be viable therapeutics for improving muscle function in SMA. About SMA
SMA is a severe neuromuscular disease that occurs in 1 in every 6,000 to 10,000 live births each year and is one of the most common fatal genetic disorders.  Spinal muscular atrophy manifests in various degrees of severity as progressive muscle weakness resulting in respiratory and mobility impairment. There are four types of SMA, named for age of initial onset of muscle weakness and related symptoms: Type I (Infantile), Type II (Intermediate), Type III (Juvenile) and Type IV (Adult onset).  Life expectancy and disease severity vary by type of SMA. Type I patients have the worst prognosis, with a life expectancy of no more than 2 years; Type IV patients have a normal life span but eventually suffer gradual weakness in the proximal muscles of the extremities resulting in mobility issues.  Few treatment options exist for these patients, resulting in a high unmet need for new therapeutic options to address symptoms and modify disease progression. About CK-2127107
Skeletal muscle contractility is driven by the sarcomere, the fundamental unit of skeletal muscle contraction. It is a highly ordered cytoskeletal structure composed of several key proteins. Skeletal muscle myosin is the cytoskeletal motor protein that converts chemical energy into mechanical force through its interaction with actin. A set of regulatory proteins, which includes tropomyosin and several types of troponin, make the actin-myosin interaction dependent on changes in intracellular calcium levels. CK-2127107, a novel skeletal muscle activator arising from Cytokinetics' skeletal muscle contractility program, slows the rate of calcium release from the regulatory troponin complex of fast skeletal muscle fibers, which sensitizes the sarcomere to calcium, leading to an increase in skeletal muscle contractility. CK-2127107 has demonstrated pharmacological activity that may lead to new therapeutic options for diseases associated with muscle weakness and fatigue.  In non-clinical models of SMA, a skeletal muscle activator has demonstrated increases in submaximal skeletal muscle force in response to neuronal input and delays in the onset and reductions in the degree of muscle fatigue.  CK-2127107 has been the subject of five completed Phase 1 clinical trials in healthy volunteers, which evaluated safety, tolerability, bioavailability, pharmacokinetics and pharmacodynamics. In addition to the Phase 2 clinical trial in patients with SMA, Cytokinetics is collaborating with Astellas on the conduct of a Phase 2 clinical trial in patients with chronic obstructive pulmonary disease. Two additional clinical trials of CK-2127107 are planned to begin in 2017, one in patients with ALS and one in elderly subjects with limited mobility. About Cytokinetics and Astellas Collaboration
In 2013, Astellas and Cytokinetics formed a partnership focused on the research, development, and commercialization of skeletal muscle activators. The primary objective of the collaboration is to advance novel therapies for diseases and medical conditions associated with muscle impairment and weakness. Under the collaboration, Cytokinetics exclusively licensed to Astellas rights to co-develop and potentially co-commercialize CK-2127107, a FSTA, in non-neuromuscular indications. In 2014, Astellas and Cytokinetics agreed to expand the collaboration to include certain neuromuscular indications, including spinal muscular atrophy (SMA), and to advance CK-2127107 into Phase 2 clinical development, initially in SMA.  The agreement was further amended in 2016 to provide Astellas exclusive rights to co-develop and commercialize CK-2127107 and other FSTAs in non-neuromuscular indications and certain neuromuscular indications (including SMA and ALS) and other novel mechanism skeletal muscle activators in all indications, subject to certain Cytokinetics’ development and commercialization rights; Cytokinetics may co-promote and conduct certain commercial activities in North America and Europe under agreed scenarios. About Cytokinetics Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal troponin activator (FSTA). Tirasemtiv is the subject of VITALITY-ALS, an international Phase 3 clinical trial in patients with ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency. Cytokinetics is preparing for the potential commercialization of tirasemtiv in North America and Europe and has granted an option to Astellas Pharma Inc. for development and commercialization in other countries. Cytokinetics is collaborating with Astellas to develop CK-2127107, a next-generation fast skeletal muscle activator.  CK-2127107 is the subject of two ongoing Phase 2 clinical trials enrolling patients with spinal muscular atrophy and chronic obstructive pulmonary disease.  Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator. Omecamtiv mecarbil is the subject of GALACTIC-HF, an international Phase 3 clinical trial in patients with heart failure. Amgen holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and certain other countries. Astellas holds an exclusive worldwide license to develop and commercialize CK-2127107. Licenses held by Amgen and Astellas are subject to Cytokinetics' specified co-development and co-commercialization rights. For additional information about Cytokinetics, visit http://www.cytokinetics.com/. Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities; the design, results, significance and utility of preclinical study results; and the properties and potential benefits of Cytokinetics’ drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trial results, patient enrollment for or conduct of clinical trials may be difficult or delayed, Cytokinetics’ drug candidates may have adverse side effects or inadequate therapeutic efficacy, the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ or its partners’ ability to conduct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Astellas’ decisions with respect to the design, initiation, conduct, timing and continuation of development activities for CK-2127107; Cytokinetics may incur unanticipated research and development and other costs or be unable to obtain additional financing necessary to conduct development of its products; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target; and risks and uncertainties relating to the timing and receipt of payments from its partners, including milestones and royalties on future potential product sales under Cytokinetics’ collaboration agreements with such partners. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.
Contact:
Cytokinetics
Diane Weiser
Vice President, Corporate Communications, Investor Relations
(415) 290-7757

Read more...
Cytokinetics Announces Additional Results From COSMIC-HF Presented at ACC.17

SOUTH SAN FRANCISCO, Calif., March 20, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (NASDAQ:CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv mecarbil in patients with chronic heart failure, were presented by Tor Biering-Sørensen, MD, PhD, Postdoctoral Research Fellow, Division of Cardiology, Brigham & Women’s Hospital and Harvard Medical School, in a Poster Session at the American College of Cardiology’s 66th Annual Scientific Session (ACC.17) in Washington, D.C. The results presented showed that omecamtiv mecarbil improved myocardial deformation, a marker of myocardial function that has been related to outcomes. Omecamtiv mecarbil, a novel investigational cardiac myosin activator that increases cardiac contractility, is being developed by Amgen in collaboration with Cytokinetics for the potential treatment of heart failure.
“These results provide the first, direct echocardiographic evidence in humans that increases in the contractility of cardiac muscle underlie the improvements in overall cardiac function observed in COSMIC-HF,” said Fady I. Malik, MD, PhD, Cytokinetics’ Executive Vice President, Research and Development. COSMIC-HF: Expansion Phase Design and Results   The expansion phase of COSMIC-HF evaluated the pharmacokinetics, pharmacodynamics, safety and tolerability of oral omecamtiv mecarbil in 448 patients with chronic heart failure and left ventricular systolic dysfunction. Patients were randomized 1:1:1 to receive either placebo or treatment with omecamtiv mecarbil dosed as 25 mg twice daily or 25 mg twice daily with dose escalation to 50 mg twice daily, depending on a plasma concentration of omecamtiv mecarbil after two weeks of treatment. The study met its primary pharmacokinetic objective and showed statistically significant improvements in all pre-specified secondary measures of cardiac function in the treatment group receiving pharmacokinetic-based (PK) dose titration. In this analysis, measures of left ventricular (LV) myocardial deformation, including global circumferential strain (GCS) and mean global longitudinal strain (GLS), were compared at baseline and at 20 weeks of treatment in the placebo group, the 25 mg twice daily group, and the PK-guided dose titration group. At 20 weeks, both mean GLS and GCS improved in the 25 mg twice daily group (p=0.014, p=0.001, respectively), and showed a trend towards improvement in the PK-guided dose titration group (p=0.06, p=0.13, respectively). These results further support that omecamtiv mecarbil directly improves myocardial contractile function. About Heart Failure Heart failure is a grievous condition that affects more than 23 million people worldwide, about half of whom have reduced left ventricular function. It is the leading cause of hospitalization and readmission in people age 65 and older. Despite broad use of standard treatments and advances in care, the prognosis for patients with heart failure is poor. An estimated one in five people over the age of 40 are at risk of developing heart failure, and approximately 50 percent of people diagnosed with heart failure will die within five years of initial hospitalization. About Omecamtiv Mecarbil Omecamtiv mecarbil is a novel cardiac myosin activator. Cardiac myosin is the cytoskeletal motor protein in the cardiac muscle cell that is directly responsible for converting chemical energy into the mechanical force resulting in cardiac contraction. Cardiac myosin activators are thought to accelerate the rate-limiting step of the myosin enzymatic cycle and shift the enzymatic cycle in favor of the force-producing state. Preclinical research has shown that cardiac myosin activators increase contractility in the absence of changes in intracellular calcium in cardiac myocytes. Omecamtiv mecarbil is being developed by Amgen in collaboration with Cytokinetics. Amgen holds an exclusive, worldwide license to omecamtiv mecarbil and related compounds, subject to Cytokinetics’ specified development and commercialization rights. Amgen has also entered an alliance with Servier for exclusive commercialization rights in Europe as well as the Commonwealth of Independent States, including Russia. Servier contributes funding for development and provides strategic support to the program. About Cytokinetics Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal troponin activator (FSTA). Tirasemtiv is the subject of VITALITY-ALS, an international Phase 3 clinical trial in patients with ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency. Cytokinetics is preparing for the potential commercialization of tirasemtiv in North America and Europe and has granted an option to Astellas Pharma Inc. for development and commercialization in other countries. Cytokinetics is collaborating with Astellas to develop CK-2127107, a next-generation fast skeletal muscle activator. CK-2127107 is the subject of two ongoing Phase 2 clinical trials enrolling patients with spinal muscular atrophy and chronic obstructive pulmonary disease.  Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator.  Omecamtiv mecarbil is the subject of GALACTIC-HF, an international Phase 3 clinical trial in patients with heart failure.  Amgen holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and certain other countries. Astellas holds an exclusive worldwide license to develop and commercialize CK-2127107. Licenses held by Amgen and Astellas are subject to Cytokinetics' specified co-development and co-commercialization rights. For additional information about Cytokinetics, visit http://www.cytokinetics.com/. Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities, including the design, results, significance and utility of COSMIC-HF clinical trial results and the potential for success and timing for the progression of omecamtiv mecarbil; and the properties and potential benefits of Cytokinetics' drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to Amgen's decisions with respect to the design, initiation, conduct, timing and continuation of development activities for omecamtiv mecarbil; potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval, including risks that patient enrollment for or conduct of clinical trials may be difficult or delayed, Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy, the U.S. Food and Drug Administration or foreign regulatory agencies may delay or limit Cytokinetics' or its partners' ability to conduct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Cytokinetics may incur unanticipated research and development and other costs or be unable to obtain additional financing necessary to conduct development of its products; standards of care may change, rendering Cytokinetics' drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact:
Cytokinetics
Diane Weiser
Vice President, Corporate Communications, Investor Relations
(650) 624-3060

Read more...
Cytokinetics Announces Presentation of Additional Results from COSMIC-HF at ACC.17

SOUTH SAN FRANCISCO, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (NASDAQ:CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv mecarbil in patients with chronic heart failure, will be presented in a poster session at the American College of Cardiology’s 66th Annual Scientific Session (ACC.17) in Washington D.C., March 17-19, 2017.
Poster Title: The Cardiac Myosin Activator, Omecamtiv Mecarbil, Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure (COSMIC-HF)
Speaker: Tor Biering-Sørensen, M.D., Ph.D., Postdoctoral Research Fellow, Division of Cardiology, Brigham & Women’s Hospital and Harvard Medical School, Boston
Session Title: 1248 - Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?
Location: Walter E. Washington Convention Center, Poster Hall, Hall C
Date: March, 18, 2017
Time: 3:45 - 4:30 PM  
Poster Number: 1248-244 About Omecamtiv Mecarbil Omecamtiv mecarbil is a novel cardiac myosin activator. Cardiac myosin is the cytoskeletal motor protein in the cardiac muscle cell that is directly responsible for converting chemical energy into the mechanical force resulting in cardiac contraction. Cardiac myosin activators are thought to accelerate the rate-limiting step of the myosin enzymatic cycle and shift the enzymatic cycle in favor of the force-producing state. Preclinical research has shown that cardiac myosin activators increase contractility in the absence of changes in intracellular calcium in cardiac myocytes. Omecamtiv mecarbil is being developed by Amgen in collaboration with Cytokinetics. Amgen holds an exclusive, worldwide license to omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization rights. Amgen has also entered an alliance with Servier for exclusive commercialization rights in Europe as well as the Commonwealth of Independent States, including Russia. Servier contributes funding for development and provides strategic support to the program. About Cytokinetics Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal troponin activator (FSTA). Tirasemtiv is the subject of VITALITY-ALS,  an international Phase 3 clinical trial in patients with ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency. Cytokinetics is preparing for the potential commercialization of tirasemtiv in North America and Europe and has granted an option to Astellas Pharma Inc. for development and commercialization in other countries. Cytokinetics is collaborating with Astellas to develop CK-2127107, a next-generation fast skeletal muscle activator.  CK-2127107 is the subject of two ongoing Phase 2 clinical trials enrolling patients with spinal muscular atrophy and chronic obstructive pulmonary disease.  Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator. Omecamtiv mecarbil is the subject of GALACTIC-HF, an international Phase 3 clinical trial in patients with heart failure. Amgen holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and certain other countries. Astellas holds an exclusive worldwide license to develop and commercialize CK-2127107. Licenses held by Amgen and Astellas are subject to Cytokinetics' specified co-development and co-commercialization rights. For additional information about Cytokinetics, visit http://www.cytokinetics.com/. Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities, including the design, results, significance and utility of GALACTIC-HF clinical trial results and the potential for success and timing for the progression of omecamtiv mecarbil; and the properties and potential benefits of Cytokinetics' drug candidates; and Cytokinetics' receipt of milestone and royalty payments from Amgen, including the timing of such payments; and the applicable royalty rate amounts on omecamtiv mecarbil that may be payable to Royalty Pharma;. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to Amgen's decisions with respect to the design, initiation, conduct, timing and continuation of development activities for omecamtiv mecarbil; potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval, including risks that patient enrollment for or conduct of clinical trials may be difficult or delayed, Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy, the U.S. Food and Drug Administration or foreign regulatory agencies may delay or limit Cytokinetics' or its partners' ability to conduct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Cytokinetics may incur unanticipated research and development and other costs or be unable to obtain additional financing necessary to conduct development of its products; standards of care may change, rendering Cytokinetics' drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact:
Cytokinetics
Diane Weiser
Vice President, Corporate Communications, Investor Relations
(650) 624-3060

Read more...

Ratios

vs
industry
vs
history
PE Ratio 46.90
CYTK's PE Ratio is ranked lower than
61% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 28.38 vs. CYTK: 46.90 )
Ranked among companies with meaningful PE Ratio only.
CYTK' s PE Ratio Range Over the Past 10 Years
Min: 6.6  Med: 12.15 Max: 46.9
Current: 46.9
6.6
46.9
PE Ratio without NRI 46.90
CYTK's PE Ratio without NRI is ranked lower than
60% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 29.63 vs. CYTK: 46.90 )
Ranked among companies with meaningful PE Ratio without NRI only.
CYTK' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.6  Med: 12.15 Max: 46.9
Current: 46.9
6.6
46.9
Price-to-Owner-Earnings 23.72
CYTK's Price-to-Owner-Earnings is ranked higher than
67% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. CYTK: 23.72 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CYTK' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 15.18  Med: 82.59 Max: 222.59
Current: 23.72
15.18
222.59
PB Ratio 6.84
CYTK's PB Ratio is ranked lower than
67% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. CYTK: 6.84 )
Ranked among companies with meaningful PB Ratio only.
CYTK' s PB Ratio Range Over the Past 10 Years
Min: 0.89  Med: 2.32 Max: 9.96
Current: 6.84
0.89
9.96
PS Ratio 6.37
CYTK's PS Ratio is ranked higher than
69% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. CYTK: 6.37 )
Ranked among companies with meaningful PS Ratio only.
CYTK' s PS Ratio Range Over the Past 10 Years
Min: 1.84  Med: 11.81 Max: 95.5
Current: 6.37
1.84
95.5
Price-to-Free-Cash-Flow 20.33
CYTK's Price-to-Free-Cash-Flow is ranked higher than
65% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. CYTK: 20.33 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CYTK' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.99  Med: 44.07 Max: 100.26
Current: 20.33
12.99
100.26
Price-to-Operating-Cash-Flow 19.36
CYTK's Price-to-Operating-Cash-Flow is ranked higher than
61% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. CYTK: 19.36 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CYTK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 12.38  Med: 39.2 Max: 89.3
Current: 19.36
12.38
89.3
EV-to-EBIT 26.03
CYTK's EV-to-EBIT is ranked lower than
54% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. CYTK: 26.03 )
Ranked among companies with meaningful EV-to-EBIT only.
CYTK' s EV-to-EBIT Range Over the Past 10 Years
Min: -18.6  Med: -1.7 Max: 724.7
Current: 26.03
-18.6
724.7
EV-to-EBITDA 25.08
CYTK's EV-to-EBITDA is ranked lower than
55% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. CYTK: 25.08 )
Ranked among companies with meaningful EV-to-EBITDA only.
CYTK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.1  Med: -1.8 Max: 364.2
Current: 25.08
-19.1
364.2
Current Ratio 4.77
CYTK's Current Ratio is ranked higher than
56% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. CYTK: 4.77 )
Ranked among companies with meaningful Current Ratio only.
CYTK' s Current Ratio Range Over the Past 10 Years
Min: 2.58  Med: 5.5 Max: 11.14
Current: 4.77
2.58
11.14
Quick Ratio 4.77
CYTK's Quick Ratio is ranked higher than
57% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CYTK: 4.77 )
Ranked among companies with meaningful Quick Ratio only.
CYTK' s Quick Ratio Range Over the Past 10 Years
Min: 2.58  Med: 5.5 Max: 11.14
Current: 4.77
2.58
11.14
Days Sales Outstanding 0.08
CYTK's Days Sales Outstanding is ranked higher than
100% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. CYTK: 0.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYTK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.06  Med: 1.05 Max: 362.71
Current: 0.08
0.06
362.71

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.70
CYTK's 3-Year Average Share Buyback Ratio is ranked higher than
55% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. CYTK: -9.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CYTK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -182.7  Med: -22.85 Max: -9.7
Current: -9.7
-182.7
-9.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 8.02
CYTK's Price-to-Net-Cash is ranked higher than
51% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. CYTK: 8.02 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CYTK' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.41  Med: 3.62 Max: 8.02
Current: 8.02
1.41
8.02
Price-to-Net-Current-Asset-Value 7.82
CYTK's Price-to-Net-Current-Asset-Value is ranked lower than
52% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. CYTK: 7.82 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CYTK' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.37  Med: 3.44 Max: 7.82
Current: 7.82
1.37
7.82
Price-to-Tangible-Book 6.85
CYTK's Price-to-Tangible-Book is ranked lower than
59% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. CYTK: 6.85 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CYTK' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.34  Med: 2.71 Max: 6.85
Current: 6.85
1.34
6.85
Price-to-Median-PS-Value 0.54
CYTK's Price-to-Median-PS-Value is ranked higher than
83% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CYTK: 0.54 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CYTK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.17  Med: 0.96 Max: 7.18
Current: 0.54
0.17
7.18
Price-to-Graham-Number 3.78
CYTK's Price-to-Graham-Number is ranked lower than
54% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 2.64 vs. CYTK: 3.78 )
Ranked among companies with meaningful Price-to-Graham-Number only.
CYTK' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.74  Med: 1.72 Max: 3.78
Current: 3.78
0.74
3.78
Earnings Yield (Greenblatt) % 3.86
CYTK's Earnings Yield (Greenblatt) % is ranked higher than
82% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. CYTK: 3.86 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CYTK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 27.35 Max: 3342.8
Current: 3.86
0.1
3342.8

More Statistics

Revenue (TTM) (Mil) $106.4
EPS (TTM) $ 0.34
Beta2.35
Short Percentage of Float8.84%
52-Week Range $7.18 - 15.90
Shares Outstanding (Mil)41.73

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 22 40 70
EPS ($) -3.23 -2.53 -2.19
EPS without NRI ($) -3.23 -2.53 -2.19
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CYTK

Headlines

Articles On GuruFocus.com
Cytokinetics Added to S&P SmallCap 600 Apr 21 2017 
Gigamon, CBL & Associates Properties and Cytokinetics Set to Join S&P SmallCap 600 Apr 17 2017 
Cytokinetics to Announce First Quarter Results on April 27, 2017 Apr 13 2017 
Cytokinetics to Present at the 16th Annual Needham Healthcare Conference Mar 29 2017 
Origent Data Sciences and Cytokinetics Advance Collaboration Intended to Validate Predictive Analyti Mar 23 2017 
Cytokinetics Announces Preclinical Data for CK-2127107 Presented at MDA Scientific Conference Mar 22 2017 
Cytokinetics Announces Additional Results From COSMIC-HF Presented at ACC.17 Mar 20 2017 
Cytokinetics Announces Presentation of Additional Results from COSMIC-HF at ACC.17 Mar 06 2017 
Cytokinetics Inc. Reports Operating Results (10-Q) Nov 04 2010 
Cytokinetics Inc. Reports Operating Results (10-Q) Aug 04 2010 

More From Other Websites
ETFs with exposure to Cytokinetics, Inc. : April 24, 2017 Apr 24 2017
Cytokinetics Added to S&P SmallCap 600 Apr 21 2017
Cytokinetics, Inc. – Value Analysis (NASDAQ:CYTK) : April 20, 2017 Apr 20 2017
Cytokinetics, Inc.: Leads amongst peers with strong fundamentals Apr 19 2017
Cytokinetics, Inc. breached its 50 day moving average in a Bullish Manner : CYTK-US : April 19, 2017 Apr 19 2017
Biotech Industry Outperforming Major Indexes in 2017: Today's Research Reports on Arena... Apr 19 2017
Why Cytokinetics, Inc. Jumped Higher Today Apr 18 2017
Gigamon, CBL & Associates Properties and Cytokinetics Set to Join S&P SmallCap 600 Apr 17 2017
Cytokinetics to Announce First Quarter Results on April 27, 2017 Apr 13 2017
Cytokinetics, Inc. breached its 50 day moving average in a Bearish Manner : CYTK-US : April 6, 2017 Apr 06 2017
Cytokinetics to Present at the 16th Annual Needham Healthcare Conference Mar 29 2017
Cytokinetics Announces Start of Second Cohort in Phase 2 Clinical Trial of CK-2127107 in Patients... Mar 29 2017
Origent Data Sciences and Cytokinetics Advance Collaboration Intended to Validate Predictive... Mar 23 2017
Cytokinetics SMA Drug Did Well in Early Study Mar 22 2017
Cytokinetics Announces Preclinical Data for CK-2127107 Presented at MDA Scientific Conference Mar 22 2017
Cytokinetics Announces Additional Results From COSMIC-HF Presented at ACC.17 Mar 20 2017
Key Indexes Rise, Steel Stocks Up Before Fed News; A Curious Trend In IBD 50 Mar 15 2017
Biotech Firm's Stock Options Complicate Its Valuation Mar 10 2017
7 Stocks Trending Up With Monster Volume Mar 09 2017
Cytokinetics Announces Presentation of Additional Results from COSMIC-HF at ACC.17 Mar 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)